Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Cleaner data confirm severe COVID-19 link to diabetes, hypertension
Initial reports that tied more severe COVID-19 disease to diabetes or hypertension used confounded data, but more refined data show similar links...
News
Terlipressin squeaks by FDA review for hepatorenal syndrome 1
The FDA advisory committee’s 8-7 vote favoring approval of terlipressin for hepatorenal syndrome type 1 reflected concerns and misgivings.
News
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’
When the SGT2 inhibitor drugs first came to the U.S. market they were labeled for just treating hyperglycemia, but those days are over.
News
Dropping race-based eGFR adjustment gains traction in U.S.
“Race is a social, not a biological, construct and the kidney-function race multiplier ignores the substantial genetic diversity within self-...
News
Neural tube defect risk from dolutegravir drops as clinical experience grows
A troubling link between the top HIV drug dolutegravir and neural tube defects, first reported in 2018, now seems much less dangerous.
News
T2D plus heart failure packs a deadly punch
Medical records from 150,000 Danish patients with type 2 diabetes showed heart failure comorbidity was the deadliest combination.
News
Belimumab safely improved renal function in lupus nephritis patients
Adding belimumab to standard SLE treatment led to better renal function after 2 years in a multicenter, randomized, controlled trial with 446...
News
Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR
Another dimension of dapagliflozin’s renal protection for type 2 diabetes patients is shown in a post-hoc analysis from its cardiovascular...
